Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Cognitive Impairment Assessment in Breast Cancer Survivors

NCT07582770 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2026-05
Last updated
2026-05-13

Condition(s) studied

Cancer Related Cognitive ImpairmentBreast Cancer Survivors

Study summary

This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 18 and 65 years old * Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop) * Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop) * Understanding of the Italian language and ability to give informed consent Exclusion Criteria: * Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop) * Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop) * Patient with a previous diagnosis of malignant carcinomas (only for control gruop) * Patient with a history of brain damage with unresolved neurological consequences * Patient with previous or current serious neurological pathologies * Patient with severe psychiatric conditions * Patient with systemic pathologies that could interfere with cognitive abilities * Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment * Patient with visual or hearing impairments that are not properly corrected * Patient with any disability that might compromise the validity of cognitive tests

Primary outcome measure(s)

  • Validation of a second-level cognitive test battery to be employed for clinical use for the detection of CRCI in breast cancer survivors — At enrollment
    Overall success rate to assess CRCI in breast cancer survivors compared with already existing tests.

Trial sites (1)

FacilityCityRegionStatus
European Institute of Oncology Milan Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07582770 on ClinicalTrials.gov ↗ ← All trials in Italy